Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

680 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells.
Galtier J, Vercellino L, Chartier L, Olivier P, Tabouret-Viaud C, Mesguich C, Di Blasi R, Durand A, Raffy L, Gros FX, Madelaine I, Meignin V, Mebarki M, Rubio MT, Feugier P, Casasnovas O, Meignan M, Thieblemont C. Galtier J, et al. Among authors: durand a. Haematologica. 2023 Jan 1;108(1):171-180. doi: 10.3324/haematol.2021.280550. Haematologica. 2023. PMID: 35678029 Free PMC article.
Risk Factors of Progression in Low-tumor Burden Follicular Lymphoma Initially Managed by Watch and Wait in the Era of PET and Rituximab.
Rodier C, Kanagaratnam L, Morland D, Herbin A, Durand A, Chauchet A, Choquet S, Colin P, Casasnovas RO, Deconinck E, Godard F, Delmer A, Rossi C, Durot E. Rodier C, et al. Among authors: durand a. Hemasphere. 2023 Apr 26;7(5):e861. doi: 10.1097/HS9.0000000000000861. eCollection 2023 May. Hemasphere. 2023. PMID: 37125257 Free PMC article.
Influence of Sociodemographic Determinants on the Hodgkin Lymphoma Baseline Characteristics in Long Survivors Patients Enrolled in the Prospective Phase 3 Trial AHL2011.
Chevreux S, de Barros S, Laurent C, Durand A, Delpierre C, Robert P, Joubert C, Griolet S, Kanoun S, Bastie JN, Casasnovas RO, Rossi C. Chevreux S, et al. Among authors: durand a. Cancers (Basel). 2022 Dec 22;15(1):53. doi: 10.3390/cancers15010053. Cancers (Basel). 2022. PMID: 36612050 Free PMC article.
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET).
Walter T, Lecomte T, Hadoux J, Niccoli P, Saban-Roche L, Gaye E, Guimbaud R, Baconnier M, Hautefeuille V, Do Cao C, Petorin C, Hentic O, Perrier M, Aparicio T, Scoazec JY, Bonjour M, Gibert B, Hervieu V, Poncet D, Barritault M, Gerard L, Durand A; “Groupe d’étude des tumeurs endocrines (GTE)” and the French ENDOCAN-RENATEN network. Walter T, et al. Among authors: durand a. J Clin Oncol. 2024 Nov 25:JCO2302724. doi: 10.1200/JCO.23.02724. Online ahead of print. J Clin Oncol. 2024. PMID: 39586038
680 results